BlossomHill Therapeutics (BLSM) shares surged over 18% on Wednesday, marking its strongest single-day performance since its August IPO. The rally followed the release of updated Phase 1/2 SOLARA trial data for lead drug BH-30643 in EGFR-mutant non-small cell lung cancer. Results showed a 45% objective response rate and 88% disease control rate among patients with specific resistance mutations, highlighting the drug's potential to overcome limitations of current EGFR inhibitors.